{"name":"PATH","slug":"path","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"oncology","drugs":[{"name":"SIIL Live Attenuated Influenza Vaccine","genericName":"SIIL Live Attenuated Influenza Vaccine","slug":"siil-live-attenuated-influenza-vaccine","indication":"Influenza prevention","status":"phase_3"},{"name":"Abhayrab rabies vaccine","genericName":"Abhayrab rabies vaccine","slug":"abhayrab-rabies-vaccine","indication":"Pre-exposure prophylaxis against rabies","status":"phase_2"},{"name":"Adjuvanted seasonal trivalent inactivated influenza vaccine","genericName":"Adjuvanted seasonal trivalent inactivated influenza vaccine","slug":"adjuvanted-seasonal-trivalent-inactivated-influenza-vaccine","indication":"Other","status":"phase_2"},{"name":"BioFarma Bivalent Oral Poliomyelitis Vaccine","genericName":"BioFarma Bivalent Oral Poliomyelitis Vaccine","slug":"biofarma-bivalent-oral-poliomyelitis-vaccine","indication":"Prevention of poliomyelitis caused by poliovirus types 1 and 3","status":"phase_3"},{"name":"ETVAX","genericName":"ETVAX","slug":"etvax","indication":"Other","status":"phase_2"},{"name":"Human Rotavirus Vaccine","genericName":"Human Rotavirus Vaccine","slug":"human-rotavirus-vaccine","indication":"Other","status":"marketed"},{"name":"LAIV H2N2","genericName":"LAIV H2N2","slug":"laiv-h2n2","indication":"Other","status":"phase_1"},{"name":"Live attenuated SA 14-14-2 vaccine","genericName":"Live attenuated SA 14-14-2 vaccine","slug":"live-attenuated-sa-14-14-2-vaccine","indication":"Japanese encephalitis prevention","status":"phase_3"},{"name":"Live, attenuated measles vaccine","genericName":"Live, attenuated measles vaccine","slug":"live-attenuated-measles-vaccine","indication":"Other","status":"marketed"},{"name":"Measles Vaccine (MV)","genericName":"Measles Vaccine (MV)","slug":"measles-vaccine-mv","indication":"Prevention of measles in children and adults","status":"marketed"},{"name":"Measles, mumps, rubella vaccine","genericName":"Measles, mumps, rubella vaccine","slug":"measles-mumps-rubella-vaccine","indication":"Prevention of measles","status":"marketed"},{"name":"Meningococcal A conjugate vaccine","genericName":"Meningococcal A conjugate vaccine","slug":"meningococcal-a-conjugate-vaccine","indication":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroup A","status":"marketed"},{"name":"Non-Adjuvanted MCV-5","genericName":"Non-Adjuvanted MCV-5","slug":"non-adjuvanted-mcv-5","indication":"Other","status":"phase_1"},{"name":"Rotavirus vaccine","genericName":"Rotavirus vaccine","slug":"rotavirus-vaccine","indication":"Prevention of rotavirus gastroenteritis in infants and young children","status":"marketed"},{"name":"Seasonal trivalent inactivated influenza vaccine","genericName":"Seasonal trivalent inactivated influenza vaccine","slug":"seasonal-trivalent-inactivated-influenza-vaccine","indication":"Seasonal influenza prevention in adults and children ≥6 months of age","status":"marketed"},{"name":"Shigella sonnei 53G","genericName":"Shigella sonnei 53G","slug":"shigella-sonnei-53g","indication":"Other","status":"phase_1"},{"name":"Vaccine produced in existing facility","genericName":"Vaccine produced in existing facility","slug":"vaccine-produced-in-existing-facility","indication":"Other","status":"marketed"},{"name":"Vaccine produced in new facility","genericName":"Vaccine produced in new facility","slug":"vaccine-produced-in-new-facility","indication":"Other","status":"marketed"},{"name":"yellow fever vaccine (YFV)","genericName":"yellow fever vaccine (YFV)","slug":"yellow-fever-vaccine-yfv","indication":"Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic countries","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Reactive Focal Drug Administration","genericName":"Reactive Focal Drug Administration","slug":"reactive-focal-drug-administration","indication":"Treatment of various cancers","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"TV P2-VP8","genericName":"TV P2-VP8","slug":"tv-p2-vp8","indication":"COVID-19","status":"phase_3"}]}],"pipeline":[{"name":"SIIL Live Attenuated Influenza Vaccine","genericName":"SIIL Live Attenuated Influenza Vaccine","slug":"siil-live-attenuated-influenza-vaccine","phase":"phase_3","mechanism":"SIIL Live Attenuated Influenza Vaccine works by exposing the body to a weakened form of the influenza virus to stimulate an immune response.","indications":["Influenza prevention"],"catalyst":""},{"name":"Abhayrab rabies vaccine","genericName":"Abhayrab rabies vaccine","slug":"abhayrab-rabies-vaccine","phase":"phase_2","mechanism":"Abhayrab rabies vaccine works by stimulating the body's immune system to produce antibodies against rabies.","indications":["Pre-exposure prophylaxis against rabies"],"catalyst":""},{"name":"Adjuvanted seasonal trivalent inactivated influenza vaccine","genericName":"Adjuvanted seasonal trivalent inactivated influenza vaccine","slug":"adjuvanted-seasonal-trivalent-inactivated-influenza-vaccine","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BioFarma Bivalent Oral Poliomyelitis Vaccine","genericName":"BioFarma Bivalent Oral Poliomyelitis Vaccine","slug":"biofarma-bivalent-oral-poliomyelitis-vaccine","phase":"phase_3","mechanism":"This bivalent oral polio vaccine stimulates mucosal and systemic immune responses against poliovirus types 1 and 3 to prevent poliomyelitis infection.","indications":["Prevention of poliomyelitis caused by poliovirus types 1 and 3"],"catalyst":""},{"name":"ETVAX","genericName":"ETVAX","slug":"etvax","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Human Rotavirus Vaccine","genericName":"Human Rotavirus Vaccine","slug":"human-rotavirus-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"LAIV H2N2","genericName":"LAIV H2N2","slug":"laiv-h2n2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Live attenuated SA 14-14-2 vaccine","genericName":"Live attenuated SA 14-14-2 vaccine","slug":"live-attenuated-sa-14-14-2-vaccine","phase":"phase_3","mechanism":"A live attenuated Japanese encephalitis virus vaccine that stimulates immune responses against Japanese encephalitis virus through controlled viral replication.","indications":["Japanese encephalitis prevention"],"catalyst":""},{"name":"Live, attenuated measles vaccine","genericName":"Live, attenuated measles vaccine","slug":"live-attenuated-measles-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Measles Vaccine (MV)","genericName":"Measles Vaccine (MV)","slug":"measles-vaccine-mv","phase":"marketed","mechanism":"The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease.","indications":["Prevention of measles in children and adults","Post-exposure prophylaxis in unvaccinated or susceptible individuals"],"catalyst":""},{"name":"Measles, mumps, rubella vaccine","genericName":"Measles, mumps, rubella vaccine","slug":"measles-mumps-rubella-vaccine","phase":"marketed","mechanism":"The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses by exposing it to attenuated (weakened) forms of these pathogens.","indications":["Prevention of measles","Prevention of mumps","Prevention of rubella"],"catalyst":""},{"name":"Meningococcal A conjugate vaccine","genericName":"Meningococcal A conjugate vaccine","slug":"meningococcal-a-conjugate-vaccine","phase":"marketed","mechanism":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A by presenting the bacterial polysaccharide capsule conjugated to a protein carrier.","indications":["Prevention of meningococcal disease caused by Neisseria meningitidis serogroup A"],"catalyst":""},{"name":"Non-Adjuvanted MCV-5","genericName":"Non-Adjuvanted MCV-5","slug":"non-adjuvanted-mcv-5","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Reactive Focal Drug Administration","genericName":"Reactive Focal Drug Administration","slug":"reactive-focal-drug-administration","phase":"marketed","mechanism":"Reactive focal drug administration is a treatment approach that targets specific areas of the body with a drug.","indications":["Treatment of various cancers"],"catalyst":""},{"name":"Rotavirus vaccine","genericName":"Rotavirus vaccine","slug":"rotavirus-vaccine","phase":"marketed","mechanism":"Rotavirus vaccine stimulates the immune system to produce antibodies and cellular immunity against rotavirus, preventing infection and severe gastroenteritis.","indications":["Prevention of rotavirus gastroenteritis in infants and young children"],"catalyst":""},{"name":"Seasonal trivalent inactivated influenza vaccine","genericName":"Seasonal trivalent inactivated influenza vaccine","slug":"seasonal-trivalent-inactivated-influenza-vaccine","phase":"marketed","mechanism":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus, providing protection against seasonal flu infection.","indications":["Seasonal influenza prevention in adults and children ≥6 months of age"],"catalyst":""},{"name":"Shigella sonnei 53G","genericName":"Shigella sonnei 53G","slug":"shigella-sonnei-53g","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"TV P2-VP8","genericName":"TV P2-VP8","slug":"tv-p2-vp8","phase":"phase_3","mechanism":"TV P2-VP8 is a vaccine candidate.","indications":["COVID-19"],"catalyst":""},{"name":"Vaccine produced in existing facility","genericName":"Vaccine produced in existing facility","slug":"vaccine-produced-in-existing-facility","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Vaccine produced in new facility","genericName":"Vaccine produced in new facility","slug":"vaccine-produced-in-new-facility","phase":"marketed","mechanism":"A vaccine produced in a new manufacturing facility that stimulates the immune system to prevent infectious disease, though the specific pathogen target is not specified.","indications":[],"catalyst":""},{"name":"yellow fever vaccine (YFV)","genericName":"yellow fever vaccine (YFV)","slug":"yellow-fever-vaccine-yfv","phase":"marketed","mechanism":"Yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain.","indications":["Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic countries"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNWjhMSnQ1MGxZNVRsWERyZVFwdEtscnZSbEpjT3pLWEVyb3J6dDJ4TWxOSVJzblJLRy1pcXY3c2RJWE9jd0dLanprYXFpSnpHNk9lVG5yNFlzTlR5c3FjemNSd3c4LVJ2c2RDUGFsdDE5N2JQR0dha1VxU1ZQdnFJTVAxNF95dE5xTmx5UmlBTHQxSFpWdHFibFdsUEZ6OFhCVkY1Y3FTcjNVZDRHYWNSUExwdlBuZlYxbC1jcHRiVVc4Ymx4bDlxaXA0cUxzYXJJYlE2RVkzMGxEQQ?oc=5","date":"2026-04-08","type":"trial","source":"Streetwise Reports","summary":"San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial - Streetwise Reports","headline":"San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQWEhmdUpVd0NqT1QyeFhFM3FDZWVFdWUwY2pmc3hHc3VBQ2ZhTHB1bzZ0Nm9ma3RtU1k5MG9sWFJqR2FPUGNkcFZOSko1dHpiWDR3Y1ZRZTdiYkZmcWNWLVdKaXVhRHpYLTh0eElTWC1tMFhiQTlVWE1lMktuaFJ3b0lVMm9aOTl1b2tkdWJmY2VtbU1WRUFsNWFUZjRpTHl2LXlWa24yTGhKQVFtQU80QjRjMUpGdThGNWVrZm12NGhfOG9tUWhYTFRpdFI?oc=5","date":"2026-03-31","type":"regulatory","source":"Investing.com","summary":"Truist reiterates Agios Pharma stock rating on accelerated approval path - Investing.com","headline":"Truist reiterates Agios Pharma stock rating on accelerated approval path","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOdG8ybnJoZ1BXeUk4ZG9uUGxiRlZIQUVYdjd3djZ1Y1ZoX3hPcHlDMGZsSG9jYmZ1V0R6X29zU1RKdmNuUlpOVEVyQWJZWlVRWFNGUU1SOEstUXJHUGFYa0VTS29DelFRTXdwTXc4T2tOWjRyNS1kaWRzRndXV0IydGlJTWpWTDRoWEFYNTdlMFhGTFdsajR6ZlI4YWNjRHBE?oc=5","date":"2026-03-11","type":"pipeline","source":"Fierce Pharma","summary":"Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales - Fierce Pharma","headline":"Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOT01QekZhTVdpcFRuZWQwVmtzQTRyLVhqQ3BVM2Fzb0ZfQzRrX3RtU0RuVDhKZkN0eEtidnREamxhWEtTMXNvQzlGaDdfdldXWFBxek56WmlNSnVfMEczSmZnWUNBQ00ybWNIcG1iT1VrY2xibm1LTk1KbWp3Vy1PY0tWTDdLREZHNEFHdVpPQ3lORjhNZTZRZXhmYzBFNFZTOEJiWEJTTWRXakJBTXVxUGNWckNCWU8zM1Q2S1NiUlpHZw?oc=5","date":"2026-03-03","type":"regulatory","source":"Seeking Alpha","summary":"X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha","headline":"X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQ2d4WTFra0JMS21DdFF4Q0pyUDh2OTVqUS1DZDY3WTRFNXZWSng0bW1LeWRfSGpWOG5RUTFrUUhNRi1SaFp6OUNsb20ybmlFMGQxQXNWd0wtY1N4aXo2ZzloVHQwYXNfYWg0S2lIM3pBSWNGU1JBQVZwQWxQR2FJZlhEWGQxdUphWXI4YnpWUmNhSVB0MmdQY0lzVkNldG96bjgwS0JvMTNwT1dFcmFRS016aU1MOGlyYk0tOWp1MDlNUQ?oc=5","date":"2026-02-12","type":"deal","source":"Pharmaceutical Commerce","summary":"Pharma Companies Left Out of Trump Drug Pricing Deals Seek Path to Avoid Tariffs - Pharmaceutical Commerce","headline":"Pharma Companies Left Out of Trump Drug Pricing Deals Seek Path to Avoid Tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNWDZtaTB1VFAwb0lpQ25KYmowQmV6RWFRY3k0N3FvSFA0SFQzcGg3eUZYQ1FFUllCclpMVDN0eTFYUkFHMmNzUk1NNVJMOW16WElNcVVKNUQxVU1LR19iS2lQMmV1UWNwUVZRdkFJLVU0WlhkaEY5OTVuSlNoNEh4NEdGMlRfWGlPSllwcHNVZDd0dk1DWEVQRllGZjF5UlZHbmZtX3lDZzN2ZmdoRmFOSGt2T0t5dlMwdWhHX09XVFdtUkRYQXY4WnpmYUE?oc=5","date":"2026-02-11","type":"deal","source":"Reuters","summary":"Pharma companies left out of Trump's drug-pricing deals look for way in - Reuters","headline":"Pharma companies left out of Trump's drug-pricing deals look for way in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFA2TUhMcUhmTm5xLWxtQUJiMjV0RE0wWFlEMmhzNTVvN0JaMWVEUmQzZFJVUnJ6eXBhbHFYMUFNb09YVEIxNzRwUm9qdS1nM1RmNUJnUDl4RjFVOHBPSUlxcWgxUk1DMGgtWGFjei1xZnJYcmxkS0VUQ0x1Zw?oc=5","date":"2026-01-23","type":"pipeline","source":"tikr.com","summary":"Pharma Mar Stock Outlook: A Path to 40% Returns - tikr.com","headline":"Pharma Mar Stock Outlook: A Path to 40% Returns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNX3BVdFRUc2hneUp5SGN0NUxvVmFGVW5pMVpiX0ZXcTBkUWhYLXdvSGEza0NET0xRd2tZcjlLUllWazZmU0s4RVdrOFJtbHpzdHplR0RmNy01N3NSWUNwX0Z6cnVIWnV5aUxKUDZvMDRtNUp2eFg4YnBhT1JHbXdZVTZkcw?oc=5","date":"2025-12-08","type":"pipeline","source":"Insilico Medicine","summary":"Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence - Insilico Medicine","headline":"Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOTlJHdEx3bnNSSFlsSlJYOXhxTVdOUkdiX1hqR3pBRTVIdG9ZNnlkdkZhNkNSV1d0ZFNQUWZITkVTVmdqRmRraldtWDFjRmlxQWppOVlGNU1BWk1OUDJSMzJPcTFoZkNUbDl4X2gtMWQtYVRWYi05VFUxVkhxNmhTcGxxSFpVb1RVd2VIVWZwNzVra09qRnFydjlZUlc0NXdkaW1DTHlEUFRRTncwbVVRa3hiNXJlQkppX2xOVmRnZUlzLVBodm5HTXpySHVEdktOLTRUSQ?oc=5","date":"2025-12-08","type":"pipeline","source":"The Detroit News","summary":"Rogers Victor: Food, not pharma: A new path for Michigan’s health - The Detroit News","headline":"Rogers Victor: Food, not pharma: A new path for Michigan’s health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQaVJNc0t5UkFXTkExbXpMVDNIeVpNSUJyNWE0UkRQeW0tZHliNTdjaElrN0RwQXhHSmZyNHNKTGRvWnMwX3NoZE00VlNIS2Y1a3ZydzhRUWFVelQtSmRIS1RrdFM0aVdJa3hWSy13aHZvaVJPaFdDSEVreXhLNnFMNUtQWGhUUQ?oc=5","date":"2025-08-25","type":"regulatory","source":"BioPharma Dive","summary":"FDA’s new accelerated pathway may open pharma up to risks, as well as benefits - BioPharma Dive","headline":"FDA’s new accelerated pathway may open pharma up to risks, as well as benefits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOa29kZHpGb25yMUNwRHFxOW01azNBTERGZFVBRkNOTDhLYUx6ajl4SjQzUklGYlBQT3BObjdsRm43VmZMRFd4dHVhbjVIV1RiYXZ3UTctQmpDQ0oxd2MtdVdVSmc2by1CZDYyY0N6d1JKYUxMUV9qWTNIUkh1SzdsZzQtRQ?oc=5","date":"2025-08-25","type":"regulatory","source":"Pharma Voice","summary":"FDA’s new accelerated pathway could open pharma up to risks, as well as benefits - Pharma Voice","headline":"FDA’s new accelerated pathway could open pharma up to risks, as well as benefits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNQzZGQy1NRWNPMmk1YUE3SDY4Vm5wLUJ3UlhKQmY2NVhWRk5mbXRyTHBZMUM5YmlZczgxZGtmZVFMcXdrTE5wdGYyZGxFQnpxYkZwM1FKM3VPRHhPbVJqOE10N25RU3ByTUpUYjJvNGU0WVFRS3dISFUxWEtSQU5vQlNiNllBeEtJdzR2a1FWaWRjRWRvX3NxcC03d2dVYUJnVkIxaF8zbzhyTWhVQ1ZqazdXdm43WTlMRjlQNW5B?oc=5","date":"2025-07-23","type":"pipeline","source":"McKinsey & Company","summary":"Bold moves, bolder vision: A CEO’s path for innovative pharma - McKinsey & Company","headline":"Bold moves, bolder vision: A CEO’s path for innovative pharma - McKinsey & Company","sentiment":"neutral"},{"date":"2007-09-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2007-05-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2007-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"phase_3":4,"phase_2":3,"marketed":11,"phase_1":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}